Intas Pharmaceuticals Limited — Atorvastatin Exporter Profile
Indian Pharmaceutical Exporter · #1 for Atorvastatin · $16.4M export value · DGFT Verified
Intas Pharmaceuticals Limited is the #1 Indian exporter of Atorvastatin with $16.4M in export value and 328 verified shipments. Intas Pharmaceuticals Limited holds a 1.5% market share in Atorvastatin exports across 10 countries. The company exports 75 pharmaceutical products worth $372.3M across 19 therapeutic categories.
Intas Pharmaceuticals Limited — Atorvastatin Export Profile: Buyers & Destinations
Where Does Intas Pharmaceuticals Limited Export Atorvastatin?
| Country | Value | Shipments | Share |
|---|---|---|---|
| CANADA | $2.5M | 108 | 51.0% |
| NETHERLANDS | $1.8M | 113 | 37.2% |
| UNITED STATES | $190.9K | 4 | 3.9% |
| GREECE | $137.2K | 12 | 2.8% |
| ZIMBABWE | $80.9K | 18 | 1.7% |
| ITALY | $71.7K | 28 | 1.5% |
| POLAND | $39.2K | 4 | 0.8% |
| MAURITIUS | $28.7K | 4 | 0.6% |
| KENYA | $25.5K | 4 | 0.5% |
| BARBADOS | $887 | 1 | 0.0% |
Intas Pharmaceuticals Limited exports Atorvastatin to 12 countries. The largest destination is CANADA accounting for 51.0% of Intas Pharmaceuticals Limited's Atorvastatin shipments, followed by NETHERLANDS (37.2%) and UNITED STATES (3.9%). These destinations reflect Intas Pharmaceuticals Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Atorvastatin from Intas Pharmaceuticals Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| TO THE ORDER | MALTA | $629.5K | 59 |
| BIOMEDPHARMA | CANADA | $594.2K | 16 |
| BROCACEF NL : HUB | NETHERLANDS | $574.0K | 45 |
| ACCORD HEALTHCARE INC., | CANADA | $374.5K | 17 |
| ACCORD HEALTHCARE INC. | CANADA | $337.0K | 27 |
| BIOMEDPHARMA 9450 BOUL LANGELIER | CANADA | $219.8K | 6 |
| NORA PHARMA INC | CANADA | $205.8K | 6 |
| ACCORD HEALTHCARE INC | CANADA | $193.7K | 14 |
| NORA PHARMA INC. | CANADA | $193.6K | 9 |
| EVERSANA LIFE SCIENCES SERVICES,LLC | UNITED STATES | $190.9K | 4 |
Intas Pharmaceuticals Limited supplies Atorvastatin to 34 buyers globally. The largest buyer is TO THE ORDER (MALTA), followed by BIOMEDPHARMA (CANADA) and BROCACEF NL : HUB (NETHERLANDS). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Atorvastatin Export Value and How Much Does Intas Pharmaceuticals Limited Contribute?
India exported $313.7M worth of Atorvastatin through 15,000 shipments from 477 suppliers to 145 countries, serving 1,291 buyers globally. Intas Pharmaceuticals Limited contributes $16.4M to this total, accounting for 1.5% of India's Atorvastatin exports. Intas Pharmaceuticals Limited ships Atorvastatin to 12 countries through 34 buyers.
What Is the Average Shipment Value for Intas Pharmaceuticals Limited's Atorvastatin Exports?
Intas Pharmaceuticals Limited's average Atorvastatin shipment value is $50.0K per consignment, based on 328 shipments totaling $16.4M. The largest destination is CANADA (51.0% of Intas Pharmaceuticals Limited's Atorvastatin exports).
How Does Intas Pharmaceuticals Limited Compare to Other Indian Atorvastatin Exporters?
Intas Pharmaceuticals Limited ranks #1 among 477 Indian Atorvastatin exporters with a 1.5% market share. The top 3 exporters are MSN LABORATORIES PRIVATE LIMITED ($83.7M), AUROBINDO PHARMA LTD ($33.2M), SUN PHARMACEUTICAL INDUSTRIES LIMITED ($32.8M). Intas Pharmaceuticals Limited processed 328 shipments to 10 destination countries.
What Atorvastatin Formulations Does Intas Pharmaceuticals Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PHARMA DRUGS & MEDI ATORVASTATIN 80MG 10 | $229.7K | 12 |
| PHARMACEUTICAL DRUGS AND MEDICINE ATORVASTATIN 10MG10X10T G1 ACO GERMANY ASPER INVOICE | $171.8K | 10 |
| PHARMA DRUGS AND MEDI BIO ATORVASTATIN 20MG AS PER INVNOS | $149.5K | 3 |
| PHARMA DRUGS & MEDI ATORVASTATIN 80MG 10X10T(ACCORD-FI/SE AS PER INVOICE | $137.2K | 7 |
| PHARM DRUG&MED:ATORVASTATIN 20MG 10X10T(ACCORD-FI/SE) EACH FILM-COATED TABLET CONTAINS 20 MG ATORVASTATIN | $103.3K | 3 |
| PHARMA DRUGS AND MEDI BIO ATORVASTATIN 20MG AS PER INV | $101.0K | 3 |
| PHARMA DRUGS & MEDI ATORVASTATIN CAL USP | $100.0K | 2 |
| PHARMA DRUGS AND MEDI BIO ATORVASTATIN 40MG 500TBIOMED#CAN AS PER INV | $100.0K | 2 |
| PH.DRU.& MED.: BIO ATORVASTATIN 40MG TABLETS (ATORVASTATIN CALCIUM TABLETS 40MG)[1X500T PER PACK] | $100.0K | 2 |
| PHARMA DRUG&MED:ATORVASTATIN 20MG 10X10T | $87.1K | 4 |
Intas Pharmaceuticals Limited exports 193 distinct Atorvastatin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PHARMA DRUGS & MEDI ATORVASTATIN 80MG 10 with 12 shipments worth $229.7K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Regulatory Requirements: Exporting Atorvastatin to Key Markets
What Intas Pharmaceuticals Limited must comply with to export Atorvastatin to its top destination countries
Canada — HC
Approval Process
ANDS (Abbreviated New Drug Submission) referencing Canadian Reference Product. Comparative bioavailability study required.
Timeline: 12–18 months
GMP & Export Requirements
Health Canada GMP (GUI-0001); Drug Establishment Licence (DEL) inspection
Drug Identification Number (DIN) for each product; Certificate of Pharmaceutical Product from CDSCO
Note: Subject to Good Import Practices and annual C.01.014.6 review.
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Intas Pharmaceuticals Limited Compare to Nearest Atorvastatin Exporters?
Exporters ranked immediately above and below #1 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | PIRAMAL PHARMA LIMITED | $21.4M | 429 | 1 | $50.0K |
| 3 | MYLAN LABORATORIES LIMITED | $16.5M | 330 | 7 | $50.0K |
| 1 | INTAS PHARMACEUTICALS LIMITED ★ | $16.4M | 328 | 10 | $50.0K |
| 10 | MEDREICH LIMITED | $14.6M | 291 | 6 | $50.0K |
| 5 | ALKEM LABORATORIES LIMITED | $13.8M | 277 | 5 | $50.0K |
Intas Pharmaceuticals Limited ranks #1 among 477 Indian Atorvastatin exporters. Average shipment value of $50.0K compared to the market average of $657.7K. The closest competitors by value are PIRAMAL PHARMA LIMITED and MYLAN LABORATORIES LIMITED.
Which Indian Ports Ship Atorvastatin Exports?
| Port | Shipments | % Share |
|---|---|---|
| HYDERABAD ICD | 2,042 | 13.6% |
| HYDERABAD ICD (INSNF6) | 1,131 | 7.5% |
| NHAVA SHEVA SEA (INNSA1) | 842 | 5.6% |
| SAHAR AIR | 839 | 5.6% |
| JNPT/ NHAVA SHEVA SEA | 779 | 5.2% |
| DELHI AIR | 613 | 4.1% |
| SAHAR AIR CARGO ACC (INBOM4) | 581 | 3.9% |
| HYDERABAD AIR | 554 | 3.7% |
What Other Cardiovascular Products Does Intas Pharmaceuticals Limited Export?
Intas Pharmaceuticals Limited also exports these cardiovascular products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Intas Pharmaceuticals Limited's Atorvastatin Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Intas Pharmaceuticals. The Israel-Iran tensions have led to increased security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major carriers to reroute shipments around the Cape of Good Hope. This detour has extended transit times by 10–20 days and raised freight rates by 40–50% on key India–Europe routes, impacting the cost-effectiveness and timeliness of exports. (livemint.com)
Conversely, the ongoing US-China trade tensions have opened avenues for Indian pharmaceutical companies to capture a larger share of the U.S. market. Intas's acquisition of UDENYCA® and the FDA's acceptance of its biosimilar applications position the company to leverage these opportunities effectively. However, compliance with the European Union's Falsified Medicines Directive (FMD) remains a critical factor for market access. Intas's proactive approach in securing partnerships and ensuring regulatory compliance underscores its commitment to maintaining and expanding its presence in the European market.
Intas Pharmaceuticals Limited — Regulatory Compliance & Quality Standards
Maintaining stringent regulatory compliance is paramount for Indian pharmaceutical exporters. Intas Pharmaceuticals has demonstrated a strong commitment to adhering to international quality standards, as evidenced by its successful acquisitions and partnerships that necessitate compliance with FDA, WHO, and EU Good Manufacturing Practices (GMP). The company's proactive engagement in regulatory processes, such as the FDA's acceptance of its Biologics License Application for DMB-3115, reflects its dedication to quality and compliance. (intaspharma.com) As global regulatory requirements continue to evolve, Intas's focus on quality assurance and compliance positions it favorably in the competitive pharmaceutical export market.
About Intas Pharmaceuticals Limited
Intas Pharmaceuticals Limited exports 75 products worth $372.3M. Beyond Atorvastatin, top products include Ras, Mycophenolate, Tacrolimus, Apixaban, Ezetimibe. View the complete Intas Pharmaceuticals Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Atorvastatin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Atorvastatin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Intas Pharmaceuticals Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 421 individual customs records matching Intas Pharmaceuticals Limited exporting Atorvastatin, covering 193 formulations to 12 countries via 34 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 145+ countries, 1,291+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Atorvastatin Export Data from Intas Pharmaceuticals Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Intas Pharmaceuticals Limited's Atorvastatin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Intas Pharmaceuticals Limited
Full Company Profile →
75 products · $372.3M total trade · 19 categories
Atorvastatin Stats
Company Overview
Top Products by Intas Pharmaceuticals Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Intas Pharmaceuticals Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Atorvastatin. For current shipment-level data, contact TransData Nexus.